+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030

  • ID: 5157424
  • Report
  • July 2020
  • Region: Global
  • 323 Pages
  • Roots Analysis

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Abzena
  • Cardinal Health
  • GE Hitachi Nuclear Energy
  • Life Molecular Imaging
  • PET Pharm Biotech
  • SWAN Isotopen
  • MORE

Overview

Since the discovery of the means to artificially synthesize radioisotopes (early 1930s), they were almost immediately adopted for healthcare applications, by the mid-1940s. Presently, a variety of diagnostic and therapeutic techniques are based on the use of such substances, commonly referred to as radiopharmaceuticals. Despite their inherent toxicity, nuclear medicine is considered an important part of modern healthcare, with applications spanning across a number of therapeutic areas, including infectious diseases, immunological disorders, gastroenteric disease, cardiological disorders, oncological disorders, neurological disorders, and even certain psychiatric conditions. According to an article published by World Nuclear Association in May 2020, more than 10,000 hospitals worldwide claim to be using radioisotopes for various medical procedures; interestingly, of the aforementioned applications, 90% were reported to be related to disease diagnosis Typically, diagnostic tests, involving radiopharmaceuticals, are performed using highly specialized imaging solutions, such as single photon emission computed tomography (SPECT) and positron emission tomography (PET). It is worth highlighting that around 40 million diagnostic procedures, involving the use of the radioisotope Tc-99m alone, are conducted worldwide annually. Further, the introduction of the concept of theranostics, which involves the use of a single active ingredient for both diagnostic and therapeutic purposes, has opened up a new dimension of applications for nuclear medicine.

Over the years, medical research teams across the world have gradually tapped into the vast potential of radiopharmaceuticals and nuclear medicines. In fact, the technology that is now used in this field is reported to have witnessed significant evolution, in terms of technological sophistication. As a result, the demand for such specialized chemicals has grown at an exponential rate. However, the development and production of radiopharmaceuticals is inherently complex, and requires specialized facilities and operational expertise. Therefore, acquiring the necessary technical acumen and infrastructure to support such operations is not a feasible option for pharmaceutical companies, owing to a number of associated clauses and concerns (such as need for high capital investments, unique operating licenses and compliance to special regulatory requirements). Currently, stakeholders in the pharmaceutical industry primarily rely on suppliers and contract manufacturers to fulfill their radiopharmaceutical procurement needs. Moreover, there are a number of specialty service providers that claim to be engaged in this field, offering a variety of radioisotopes and affiliated services for healthcare applications. As more applications are discovered, the demand for nuclear material suppliers and service providers is likely to increase. This, coupled to the anticipated advances in the field of radiopharmaceuticals, affiliated technologies and products, is expected to offer lucrative opportunities to the contract service providers that are engaged in this domain.

Scope Of the Report

The ‘Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030’ report provides a detailed study on the current market landscape and future potential of the companies having the capabilities to manufacture radiopharmaceuticals. In addition, the study features an in-depth analysis, highlighting the capabilities of a diverse set of industry stakeholders. Amongst other elements, the report features the following:

  • A detailed assessment of the current market landscape with respect to the players (industry and non-industry) involved in manufacturing radiopharmaceuticals. It features information on the year of establishment, company size, purpose of production (fulfilling in-house requirements / for contract services), location of headquarters, location of manufacturing facilities, scale of production, applications of radiopharmaceuticals (in diagnosis, therapeutics and theranostics), type of diagnostic radiopharmaceuticals (PET and SPECT), type of therapeutic radiopharmaceuticals (alpha emitters, beta emitters and others), target therapeutic area (cardiology, oncology, neurology, thyroid and others) and services offered.
  • An insightful four-dimensional comparison of the radiopharmaceutical manufacturers, based on supplier power (year of establishment), product portfolio (number of isotopes being manufactured for various applications targeting different therapeutic areas) of the manufacturer, scale at which they manufacture their respective products and company size.
  • Tabulated profiles of key industry players based in North America, Europe and Asia-Pacific (shortlisted based on the company size of the players), featuring a brief overview of the company, a list of products and manufacturing facilities, recent developments and an informed future outlook.
  • An analysis of recent partnerships and collaborations inked in this domain since 2017, based on several parameters, such as the type of partnership, year of partnership, type of radioisotope involved, therapeutic area mentioned in the agreement,  application of the radioisotope mentioned in the agreement, and a schematic representation showcasing the players that have forged the maximum number of alliances. Furthermore, we have provided a world map representation of the deals inked in this field, highlighting those that have been established within and across different continents.
  • A detailed discussion on the supply chain model of medical isotope Mo-99 (Tc-99m), highlighting the main steps of the supply chain, from irradiation of uranium targets in nuclear research reactors to the administration of Tc-99m to patients. Along with this, it describes the structure of the industry and product market at each step.

One of the key objectives of this report was to evaluate the current market size and the future opportunity associated with the radiopharmaceutical manufacturing market, over the coming decade. Based on various parameters, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2020-2030. The report also provides details on the likely distribution of the current and forecasted opportunity across [A] target therapeutic area (cardiology, neurology, oncology, thyroid and others), [B] application area (diagnostic and therapeutic) and [C] type of diagnostic radiopharmaceuticals (PET and SPECT), [D] type of therapeutic radiopharmaceuticals (alpha emitters, beta emitters and others), [E] purpose of production (in-house/outsourcing) and [F] key geographical regions (North America, Europe, Asia-Pacific and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals (arranged in the order of participant’s designation):

  • James Davis (Vice President Quality / R&D, Shertech Laboratories)
  • Andreas Fotopoulos (Professor of Nuclear Medicine, University of Ioannina Medical School)
  • Jan Pruim (Professor of Medical Imaging / Nuclear Medicine Physician, University Medical Center of Groningen)
  • Michael van Dam (Professor, Crump Institute for Molecular Imaging, Molecular & Medical Pharmacology)
  • Anonymous (ITM Isotopen Technologien München)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the leading industry and non-industry players engaged in the nuclear medicine and radiopharmaceutical manufacturing market?
  • For which application and disease indications are the radiopharmaceuticals being manufactured?
  • What are the various type of radionuclides being manufactured for the formulation of radiopharmaceuticals?
  • What is the relative competitiveness of manufacturers involved in the nuclear medicine and radiopharmaceutical manufacturing?
  • Which partnership models are commonly adopted by the radiopharmaceutical manufacturers in this industry?
  • What is the supply chain process for medical isotope Mo-99 / Tc-99m?
  • What are the key factors that are likely to influence the evolution of the nuclear medicine and radiopharmaceutical manufacturing market?         
  • How is the current and future market opportunity likely to be distributed across key market segments?
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abzena
  • Cardinal Health
  • GE Hitachi Nuclear Energy
  • Life Molecular Imaging
  • PET Pharm Biotech
  • SWAN Isotopen
  • MORE

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Nuclear Medicines and Radiopharmaceuticals
3.3. Historical Evolution of Radiopharmaceuticals
3.4. Applications of Radiopharmaceuticals
3.4.1. Nuclear Imaging / Diagnosis
3.4.1.1. Single Photon Emission Computed Tomography
3.4.1.2. Positron Emission Tomography
3.4.2. Therapeutic Use
3.5. Production of Radiopharmaceuticals
3.5.1. Radionuclide Generator
3.5.2. Particle Accelerator (Cyclotron)
3.5.3. Nuclear Reactor
3.6. Regulatory Framework for Radiopharmaceuticals
3.6.1. Guidelines for the Production of Radiopharmaceuticals
3.6.2. Guidelines for Labelling and Packaging of Radiopharmaceuticals
3.6.3. Guidelines for Storage of Radiopharmaceuticals
3.7. Need for Outsourcing Radiopharmaceuticals Manufacturing
3.8. Selecting a CMO Partner for Radiopharmaceuticals Manufacturing
3.9. Current Scenario and Future Prospects Related to Radiopharmaceuticals

4. NUCLEAR MEDICINE AND RADIOPHARMACEUTICALS MANUFACTURERS (INDUSTRY PLAYERS): CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Nuclear Medicine and Radiopharmaceuticals Manufacturers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Purpose of Production
4.2.4. Analysis by Geographical Location of Headquarters
4.2.5. Analysis by Geographical Location of Manufacturing Facilities
4.2.6. Analysis by Scale of Production
4.2.7. Analysis by Application Area
4.2.8. Analysis by Type of Radioisotope
4.2.8.1. Radioisotopes for Diagnostic Use
4.2.8.2. Radioisotopes for Therapeutic Use
4.2.9 Analysis by Target Therapeutic Area
4.2.10 Analysis by Service(s) Offered

5. NUCLEAR MEDICINE AND RADIOPHARMACEUTICALS MANUFACTURERS (NON-INDUSTRY PLAYERS): CURRENT MARKET LANDSCAPE
5.1. Chapter Overview
5.2. Nuclear Medicine and Radiopharmaceuticals Manufacturers: Overall Market Landscape
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Purpose of Production
5.2.3. Analysis by Geographical Location of Manufacturing Facilities
5.2.4. Analysis by Scale of Production
5.2.5. Analysis by Application Area
5.2.6. Analysis by Type of Radioisotopes
5.2.6.1. Radioisotopes for Diagnostic Use
5.2.6.2. Radioisotopes for Therapeutic Use

6. NUCLEAR MEDICINE AND RADIOPHARMACEUTICALS MANUFACTURERS IN NORTH AMERICA
6.1. Chapter Overview
6.2. Cardinal Health
6.2.1. Company Overview
6.2.2. List of Products and Manufacturing Facilities
6.2.3. Recent Developments and Future Outlook
6.3. GE Healthcare
6.3.1. Company Overview
6.3.2. List of Products and Manufacturing Facilities
6.3.3. Recent Developments and Future Outlook
6.4. Jubilant Radiopharma
6.4.1. Company Overview
6.4.2. List of Products and Manufacturing Facilities
6.4.3. Recent Developments and Future Outlook
6.5. Lantheus Medical Imaging
6.5.1. Company Overview
6.5.2. List of Products and Manufacturing Facilities
6.5.3. Recent Developments and Future Outlook
6.6. Nordion
6.6.1. Company Overview
6.6.2. List of Products and Manufacturing Facilities
6.6.3. Recent Developments and Future Outlook
6.7. SOFIE
6.7.1. Company Overview
6.7.2. List of Products and Manufacturing Facilities
6.7.3. Recent Developments and Future Outlook

7. NUCLEAR MEDICINE AND RADIOPHARMACEUTICALS MANUFACTURERS IN EUROPE
7.1. Chapter Overview
7.2. Advanced Accelerator Applications
7.2.1. Company Overview
7.2.2. List of Products and Manufacturing Facilities
7.2.3. Recent Developments and Future Outlook
7.3. SCK - CEN
7.3.1. Company Overview
7.3.2. List of Products and Manufacturing Facilities
7.3.3. Recent Developments and Future Outlook
7.4. Curium Pharma
7.4.1. Company Overview
7.4.2. List of Products and Manufacturing Facilities
7.4.3. Recent Developments and Future Outlook
7.5. Eckert & Ziegler
7.5.1. Company Overview
7.5.2. List of Products and Manufacturing Facilities
7.5.3. Recent Developments and Future Outlook
7.6. PETNET Solutions
7.6.1. Company Overview
7.6.2. List of Products and Manufacturing Facilities
7.6.3. Recent Developments and Future Outlook

8. NUCLEAR MEDICINE AND RADIOPHARMACEUTICALS MANUFACTURERS IN ASIA-PACIFIC AND REST OF THE WORLD
8.1. Chapter Overview
8.2. China Isotope & Radiation Corporation
8.2.1. Company Overview
8.2.2. List of Products and Manufacturing Facilities
8.2.3. Recent Developments and Future Outlook
8.3. DuChemBio
8.3.1. Company Overview
8.3.2. List of Products and Manufacturing Facilities
8.3.3. Recent Developments and Future Outlook
8.4. Eczacibasi-Monrol
8.4.1. Company Overview
8.4.2. List of Products and Manufacturing Facilities
8.4.3. Recent Developments and Future Outlook
8.5. Nihon Medi-Physics
8.5.1. Company Overview
8.5.2. List of Products and Manufacturing Facilities
8.5.3. Recent Developments and Future Outlook
8.6. Sinotau Pharmaceuticals
8.6.1. Company Overview
8.6.2. List of Products and Manufacturing Facilities
8.6.3. Recent Developments and Future Outlook

9. NUCLEAR MEDICINE AND RADIOPHARMACEUTICALS MANUFACTURERS: COMPANY COMPETITIVENESS ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Assumptions and Key Parameters
9.4. Four-Dimensional Bubble Analysis based on Supplier Power, Product Portfolio Strength and Manufacturing Capabilities
9.4.1. Nuclear Medicine and Radiopharmaceuticals Manufacturers based in North America
9.4.2 Nuclear Medicine and Radiopharmaceuticals Manufacturers based in Europe
9.4.3. Nuclear Medicine and Radiopharmaceuticals Manufacturers based in Asia-Pacific and Rest of the World

10. PARTNERSHIPS AND COLLABORATIONS
10.1. Chapter Overview
10.2. Partnership Models
10.3. Nuclear Medicine and Radiopharmaceuticals Manufacturers: Partnerships and Collaborations
10.3.1. Analysis by Type of Partnership
10.3.2. Analysis by Year of Partnership
10.3.3. Analysis by Type of Radioisotope
10.3.4. Analysis by Target Therapeutic Area Mentioned in the Agreement
10.3.5. Analysis by Application Mentioned in the Agreement
10.3.6. Most Active Players: Analysis by Number of Partnerships
10.3.7. Geographical Analysis
10.3.8. Intercontinental and Intracontinental Agreements

11. PRODUCTION AND SUPPLY CHAIN OF MEDICAL ISOTOPE MOLYBDENUM-99 (TECHNETIUM-99M)
11.1. Chapter Overview
11.2. Production and Use of Mo-99
11.2.1. Reactor-based Production
11.2.2. Accelerator-based Production
11.3. Supply Chain of Mo-99
11.3.1. Target Suppliers
11.3.2. Irradiation Service Providers
11.3.3. Mo-99 Suppliers
11.3.4. Technetium Generator Suppliers
11.3.5. Tc-99m End-Users
11.4. Future Prospects

12. MARKET FORECAST AND OPPORTUNITY ANALYSIS
12.1. Chapter Overview
12.2. Forecast Methodology and Key Assumptions
12.3. Overall Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030
12.3.1. Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030: Distribution by Target Therapeutic Area
12.3.2. Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030: Distribution by Application Area
12.3.3. Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030: Distribution by Diagnostic Radiopharmaceuticals
12.3.4. Nuclear Medicine and Radiopharmaceutical Manufacturing Market, 2020-2030: Distribution by Therapeutic Radiopharmaceuticals
12.3.5. Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030: Distribution by Purpose of Production
12.3.6. Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030: Distribution by Key Geographical Regions

13. CONCLUDING REMARKS
13.1. Chapter Overview
13.2. Key Takeaways

14. EXECUTIVE INSIGHTS
14.1. Chapter Overview
14.2. Shertech Laboratories
14.2.1. Company Snapshot
14.2.2. Interview Transcript: James Davis, Vice President Quality / R&D
14.3. University of Ioannina
14.3.1. Organization Snapshot
14.3.2. Interview Transcript: Andreas Fotopoulos, Professor of Nuclear Medicine
14.4. University Medical Center Groningen
14.4.1. Organization Snapshot
14.4.2. Interview Transcript: Jan Pruim, Professor of Medical Imaging / Nuclear Medicine Physician
14.5. Crump Institute for Molecular Imaging, Molecular & Medical Pharmacology
14.5.1. Organization Snapshot
14.5.2. Interview Transcript: Michael van Dam, Professor
14.6. ITM Isotopen Technologien München
14.6.1. Company Snapshot
14.6.2. Interview Transcript: Anonymous

15. APPENDIX 1:  TABULATED DATA

Note: Product cover images may vary from those shown
  • 3D Imaging Drug Design and Development
  • ABX advanced biochemical compounds
  • Abzena
  • Advanced Accelerator Applications
  • Advanced Nuclear Medicine Ingredients
  • Ahmanson Translational Imaging Division
  • Alliance Medical
  • Alpha Tau
  • Arronax
  • ARTMS Products
  • ASAN Medical Center
  • Atlab Pharma
  • ATONCO
  • Australian Nuclear Science and Technology Organisation
  • Avid Radiopharmaceuticals
  • Bar-Ilan University
  • Bayer
  • Biomedical Research Imaging Center, UNC School of Medicine
  • Bio-Nucleonics
  • Blue Earth Diagnostics
  • Board of Radiation and Isotope Technology
  • Bracco Diagnostics
  • Bruce Power
  • BWX Technologies
  • Cameco
  • Canadian Nuclear Isotope Council
  • Cancer Targeted Technology
  • Cardinal Health
  • Center for Molecular and Genomic Imaging, UC Davis
  • Center for Neurosciences, The Feinstein Institute
  • Center for Radiochemistry Research, OHSU Knight Cardiovascular Institute
  • Center for Systems Imaging Core, Emory University
  • Centre for Advanced Imaging, The University of Queensland
  • Centre for In Vivo Imaging, Newcastle University
  • Centre for Probe Development and Commercialization
  • Cerveau Technologies
  • Chengdu Gaotong Isotope
  • Chengdu New Radiomedicine Technology
  • China Isotope & Radiation Corporation
  • Clinical Imaging Research Centre, National University of Singapore
  • Crump Cyclotron and Radiochemistry Technology Center,University of California
  • Curium Pharma
  • Cyclopharma
  • Cyclotek
  • Cyclotope Radiopharmacy
  • Cyclotron & Radiochemistry Facility, Stanford University School of Medicine
  • Cyclotron and Radiochemistry Facility, Citigroup Biomedical Imaging Center of Weill Cornell Medicine
  • Cyclotron and Radiochemistry Facility, UT Southwestern Medical Center
  • Cyclotron and Radiochemistry Laboratories, Keck School of Medicine of USC
  • Cyclotron and Radiopharmaceutical Core, Houston Methodist Research Institute
  • Cyclotron and Radiopharmaceuticals Department, King Faisal Specialist Hospital and Research Centre
  • Cyclotron Facility, University  of Chicago
  • Cyclotron Radiochemistry Facility, MD Anderson Cancer Center
  • Department of Molecular and Medical Pharmacology, University of California
  • Department of Nuclear Medicine and PET, Liverpool Hospital
  • Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine
  • Department of Nuclear Medicine, School of Health Sciences, University of Ioannina
  • Department of Radiology & Biomedical Imaging, University of California
  • Department of Radiology, The University of Alabama at Birmingham
  • Department of Radiology, University of Colorado
  • Department of Radioplogy, Penn Medicine, University of Pennsylvania
  • Dongcheng Biochemicals
  • DuChemBio
  • Eckert & Ziegler
  • Eczacibasi-Monrol
  • Endocyte
  • Essential Isotopes
  • Framatome
  • FUJIFILM Toyama Chemical
  • FutureChem
  • GE Healthcare
  • GE Hitachi Nuclear Energy
  • Global Medical Solutions
  • Global Morpho Pharma
  • Grupo RPH
  • HealthTrust
  • Heidelberg Pharma
  • Heidelberg University Hospital
  • Huntsman Cancer Institute Center for Quantitative Cancer Imaging, Univeristy of Utah Health
  • IASON
  • ImaginAb
  • Imaging Facilities, The University of Manchester
  • Inserm
  • Institut National des Radioéléments
  • Institute for Energy Technology
  • Institute of Applied Radiopharmacy of Barcelona
  • Institute of Isotopes (IZOTOP)
  • Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf
  • International Isotopes
  • IRE ELiT- Radiopharmaceuticals
  • Iso-Tex Diagnostics
  • IsoTherapeutics
  • Isotopia Molecular Imaging
  • Itelpharma
  • iThemba LABS
  • ITM Isotopen Technologien München
  • Jubilant Radiopharma
  • Kinectrics
  • Korea Insititute of Radiological & Medical Sciences
  • Kresge Cyclotron/PET Facility, Department of Radiology, University of Michigan
  • Lantheus Medical Imaging
  • Life Molecular Imaging
  • Macquarie University
  • Mallinckrodt Institute of Radiology, PET Nuclear Pharmacy and Cyclotron Facility, Washington University
  • Mallinckrodt Nuclear Imaging
  • Map Medical Technologies
  • Mayo Clinic
  • McMaster University Cyclotron Facility
  • Medi-Radiopharma
  • Memorial Sloan Kettering Cancer Center
  • Merck
  • Micro-Rad
  • Molecular Imaging Institute (M2i)
  • NanoMab Technology
  • National Centre for Nuclear Research Radioisotope Centre (POLATOM)
  • NCMUSA
  • Nihon Medi-Physics
  • Ningbo Junan Pharmaceuticals Technology
  • Nordal Cyclotron & PET Radiochemistry,  Lawson Health Research Institute
  • Nordic Nanovector
  • Nordion
  • Norsk Medisinsk
  • Novartis
  • NTP Radioisotopes
  • Nuclear and Energy Research Institute
  • Nuclear Medicine and Molecular Imaging, University of Groningen
  • Nuclear Medicine/Biomedical Imaging Research Core, Brigham and Women's Hospital
  • Nuclear Research Institute Rez
  • Nucleis Radiopharmaceuticals
  • OncoBeta
  • Ontario Power Generation
  • PET Center, Columbia University
  • PET Core, Gordan Center for Medical Imaging, Harvard Medical School
  • PET Pharm Biotech
  • PET Radiochemistry and Radiopharmacy, University of Oxford
  • PET Research Core, Renaissance School of Medicine, Stony Brook University
  • PET Research Facility, Wake Forest School of Medicine
  • PET Research Radiochemistry, University of Ottawa
  • PETNET Solutions
  • PetTecH Solutions
  • Piramal Imaging
  • PositronPharma
  • Premier
  • Progenics Pharmaceuticals
  • Q BioMed
  • Radboud University Medical Center
  • Radiochemistry & Molecular Imaging Probes Core Facility, Memorial Sloan Kettering Cancer Center
  • Radiochemistry Core, University of Virginia
  • Radiochemistry Core, Vanderbilt University Institute of Imaging Science
  • Radiochemistry Facility, Loma Linda University
  • Radiochemistry Unit, University of Helsinki
  • RadioMedix
  • Radiopharmaceutical Core Facility, Case Western Reserve University
  • Radiopharmazeutische Wissenschaften, Division of Nuclear Medicine at the Medical University of Vienna
  • RadLink Asia
  • Research Imaging Institute, University of Teaxs Health Science Center
  • Rosatom State Atomic Energy Corporation
  • ROTOP Pharmaka
  • Saskatchewan Centre for Cyclotron Sciences
  • SCK•CEN
  • Seibersdorf Laboratories
  • Shertech Nuclear
  • Sinotau Pharmaceutical
  • Societatea Nationala Nuclearelectrica
  • SOFIE
  • SpectronRx
  • SWAN Isotopen
  • Techna Institute
  • Telix Pharmaceuticals
  • The McConnell Brain Imaging Centre, University of McGrill
  • Theragnostics
  • Therapeia
  • Thunder Bay Cyclotron and Radiochemistry Laboratories, Lakehead University
  • Tong Xing
  • Toyama Chemical
  • Triad Isotopes
  • Turku PET Centre
  • United Imaging Healthcare
  • University of Melbourne
  • University of Missouri
  • University of Washington Radiochemistry Resources
  • USC Molecular Imaging Center, University of Southern California
  • Vect-Horus
  • Westinghouse Partners
  • Wolfson Brain Imaging Centre, University of Cambridge
  • Xcision
  • Y-mAbs Therapeutics
  • Zevacor Molecular
  • Zionexa
Note: Product cover images may vary from those shown

 

 

Loading
LOADING...

Adroll
adroll